GENETIC TESTING FIRM 23ANDME CUTS 40% OF ITS WORKFORCE AMID FINANCIAL STRUGGLES

Summary from the TLDR newsletter

23andMe is cutting around 200 employees and will discontinue further development of its therapies as part of a restructuring program.